德拉沙星临床综述:一种新型阴离子氟喹诺酮类药物
德拉沙星是一种新型阴离子氟喹诺酮类药物,获批用于治疗由包括MRSA和铜绿假单胞菌在内的多种革兰阳性和革兰阴性菌引起的急性细菌性皮肤及皮肤结构感染(ABSSSI)。III期研究显示其治疗ABSSSI的结局与对照方案相似且总体耐受良好,对细胞色素P450酶和校正QT间期影响极小。
要点
- 德拉沙星获批用于治疗由MRSA和铜绿假单胞菌等引起的ABSSSI。
- III期研究中德拉沙星治疗ABSSSI的结局与对照方案相似,总体耐受良好。
- 德拉沙星对细胞色素P450酶和校正QT间期影响极小,有别于其他氟喹诺酮类。
核心结论
- 德拉沙星是一种新型阴离子氟喹诺酮类药物,获批用于治疗由包括MRSA和铜绿假单胞菌在内的多种革兰阳性和革兰阴性菌引起的ABSSSI。
- 该新型氟喹诺酮类药物有潜力在多种临床场景中应用,但上市后监测及长期安全性和耐药性数据对确定最佳使用场景至关重要。
研究设计与样本
- 本文为临床综述,总结德拉沙星的化学结构、抗菌活性、药代动力学、III期研究结果及安全性特征。
主要发现
- 德拉沙星独特的化学结构使其成为弱酸,在酸性环境中效力增强。
- III期研究中,德拉沙星治疗ABSSSI的结局与对照方案相似,且总体耐受良好。
- 与其他氟喹诺酮类药物相似,德拉沙星有静脉和口服两种剂型,但对细胞色素P450酶和校正QT间期影响极小。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Delafloxacin is a novel anionic fluoroquinolone (FQ) approved for treatment of acute bacterial skin and skin structure infections (ABSSSIs) caused by a number of Gram-positive and Gram-negative organisms including MRSA and Pseudomonas aeruginosa. The unique chemical structure of delafloxacin renders it a weak acid and results in increased potency in acidic environments. In Phase III studies, delafloxacin had similar outcomes to comparator regimens for treatment of ABSSSIs, and was well tolerated overall. Similar to other FQs, delafloxacin is available in both intravenous and oral formulations, but differs in that delafloxacin exerts a minimal effect on cytochrome P450 enzymes and on the corrected QT interval. This novel FQ has the potential to be utilized across a wide variety of clinical settings; however, post-marketing surveillance and long-term safety and resistance data will be essential to identify optimal use scenarios.
引用
- Mogle BT, Steele JM, Thomas SJ, et al. Clinical review of delafloxacin: a novel anionic fluoroquinolone. J Antimicrob Chemother. 2018. PMID: 29425340. doi:10.1093/jac/dkx543
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。